leukemia therapy (Deltagen/University of Kentucky)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Nameleukemia therapy (Deltagen/University of Kentucky)
Drug Alias NameCD123 antibody (Deltagen)antibody therapy (Deltagen/University of Kentucky)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionInterleukin-3 receptor subunit alpha inhibitors
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Kentucky
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDeltagen IncUniversity Of Kentucky
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A